The results of our study demonstrate that insulin Faster Aspart is a valid alternative to Aspart to safely and effectively manage postprandial hyperglycemia in patients with type 1 diabetes, potentially providing more effective control of glycemic values in the three hours following a meal regardless of its glycemic index. This evidence concerns the gene INS and Hyperglycemia.